Roland Veltkamp received his clinical training as a stroke neurologist in Heidelberg, Germany, and at Wake Forest University School of Medicine, USA. His research interests encompass emergency therapy of ischemic and hemorrhagic stroke and stroke prevention in atrial fibrillation. His research has led to new methods of Afib detection on the stroke unit and to the improvement of acute stroke management in patients on anticoagulants. His translational stroke research group investigates the role of the immune system after stroke. In a landmark study, his group has described a major protective role of regulatory T cells in experimental stroke. Recent findings in his laboratory have led to a phase II clinical stroke trial testing the effect of the leukocyte adhesion blocker natalizumab in stroke.
Currently, Prof. Veltkamp serves as a member of the Board of Directors of the European Stroke Organisation and is an international delegate of the program committee of the AHA International Stroke Conference.
et al., 2018, Expert opinion paper on atrial fibrillation detection after ischemic stroke, Clinical Research in Cardiology, Vol:107, ISSN:1861-0684, Pages:871-880
et al., 2018, Microbleeds in ischemic vs hemorrhagic strokes on novel oral anticoagulants, Acta Neurologica Scandinavica, Vol:138, ISSN:0001-6314, Pages:163-169
et al., 2018, Clinical significance of cerebral microbleeds on MRI: A comprehensive meta-analysis of risk of intracerebral hemorrhage, ischemic stroke, mortality, and dementia in cohort studies (v1), International Journal of Stroke, Vol:13, ISSN:1747-4930, Pages:454-468
et al., 2018, Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source, New England Journal of Medicine, Vol:378, ISSN:0028-4793, Pages:2191-2201
et al., 2018, Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial, Journal of Stroke & Cerebrovascular Diseases, Vol:27, ISSN:1052-3057, Pages:1673-1682